missing translation for 'onlineSavingsMsg'
Läs mer
Läs mer
STEMCELL Technologies LY2228820 (Dimesylate)
Beskrivning
- LY2228820 is a trisubstituted imidazole derivative and a potent inhibitor of the α- and β-isoforms of p38 MAP kinase (MAPK) in vitro (IC50 = 5.3 and 3.2 nM, respectively) with anti-inflammatory and anti-neoplastic activities (Campbell et al.) This product is supplied as the dimesylate salt of the molecule
- Combined with other small molecule inhibitors such as Rapamycin (Catalog #73362) and SR1 (Catalog #72342; Li et al.) or SB203580 (Catalog #72222), Vx702, and BIRB-796 (Catalog #72682), enhances the self-renewal of cord blood-derived hematopoietic stem cells (Baudet et al.)
- By inhibiting p38 MAPK, which is highly expressed in human cancers, LY2228820 is potent and selective at inhibiting tumor growth in animal models of a variety of human cancers (Campbell et al.)
Specifikationer
Specifikationer
| CAS | 862507-23-1 |
| Synonym | Ralimetinib Mesylate; LSN2322600 |
| Kvantitet | 5 mg |
| Molekylformel | C24H29FN6 · 2CH3SO3H |
| Renhet | ≥98% |
Produkttitel
Genom att klicka på Skicka bekräftar du att du kan bli kontaktad av Fisher Scientific angående feedbacken du har lämnat i detta formulär. Vi kommer inte att dela din information för andra ändamål. All kontaktinformation som tillhandahålls ska också underhållas i enlighet med vår Sekretesspolicy.
Hittar du en möjlighet till förbättring?